GH Research (GHRS) Return on Capital Employed (2021 - 2026)
GH Research (GHRS) posted quarterly Return on Capital Employed of 21.17% for Q4 2025, up 602.0% year-over-year from 3.02% in Q4 2024, and down 10.56% quarter-over-quarter from 19.15% in Q3 2025.
GH Research (GHRS) Return on Capital Employed (2021 - 2026) Analysis & Trends
GH Research's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 21.17% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 602.0% year-over-year to 21.17%; the TTM figure through Dec 2025 stood at 21.17% (up 602.0% YoY), while the FY2025 annual figure was 26.41%, down 105.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 21.17%, down from 19.15% in the prior quarter.
- The five-year high for Return on Capital Employed was 5.33% in Q4 2021, with the low at 27.2% in Q4 2024.
- The 5-year median for Return on Capital Employed is 17.27% (2025), against an average of 16.65%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 869 bps in 2024, then jumped 602 bps in 2025.
- GH Research's Return on Capital Employed stood at 5.33% in 2021, then plunged by 127 bps to 12.09% in 2022, then plunged by 53 bps to 18.51% in 2023, then sank by 47 bps to 27.2% in 2024, then advanced by 22 bps to 21.17% in 2025.
- Business Quant data shows GHRS's Return on Capital Employed at 21.17% in Q4 2025, 19.15% in Q3 2025, and 17.27% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | -21.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.25% |
| Dec 31, 2025 | -21.17% |
| Sep 30, 2025 | -19.15% |
| Jun 30, 2025 | -17.27% |
| Mar 31, 2025 | -21.07% |
| Dec 31, 2024 | -27.20% |
| Sep 30, 2024 | -25.08% |
| Jun 30, 2024 | -22.31% |
| Mar 31, 2024 | -19.72% |
| Dec 31, 2023 | -18.51% |
| Sep 30, 2023 | -17.04% |
| Jun 30, 2023 | -15.17% |
| Mar 31, 2023 | -13.45% |
| Dec 31, 2022 | -12.09% |
| Sep 30, 2022 | -10.78% |
| Jun 30, 2022 | -9.76% |
| Mar 31, 2022 | -7.94% |
| Dec 31, 2021 | -5.33% |